Protein and peptide drugs
Since the success with the production of recombinant insulin for treatment of diabetes, we have succeeded in the generation of chimeric antibodies, humanized antibodies and complete human antibodies that are able to treat a rapidly growing number of diseases. Phage display technology along with advanced recombinant protein strategies have advanced the field since early 2000.
Novel targets and protein designs are constantly evolving and novel strategies for drug delivery to improve efficacy and reduce toxicity is key to the future success. The protein and peptide drug groups headed by Associate senior lecturer Greta Hultqvist and Associate senior lecturer Sara Mangsbo center around protein/peptide drug therapeutics with a focus on utilizing passive and active immunotherapy approaches to treat diseases like Alzheimer and bladder cancer. Their work center around innovative strategies to improve protein drugs and advanced characterization of the biology behind the therapeutic efficacy achieved by the novel drug entity.